Octagon Capital Advisors
Latest statistics and disclosures from Octagon Capital Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are APLS, ALPN, DNTH, VRNA, DYN, and represent 40.84% of Octagon Capital Advisors's stock portfolio.
- Added to shares of these 10 stocks: Arrivent Biopharma (+$35M), DNTH (+$25M), EYPT (+$23M), OCUL (+$22M), MNMD (+$20M), CATX (+$18M), CRBP (+$16M), PRAX (+$16M), TNYA (+$15M), JSPR (+$15M).
- Started 33 new stock positions in CATX, AKRO, ALLO, TERN, Arrivent Biopharma, VTYX, MNMD, IPSC, SLN, JSPR.
- Reduced shares in these 10 stocks: Cymabay Therapeutics (-$63M), RCUS (-$36M), CLDX (-$28M), ROIV (-$28M), Gracell Biotechnologies (-$6.0M), INSM, Jasper Therapeutics, INZY, XLO, MIRM.
- Sold out of its positions in ACRS, RCUS, CLDX, Cymabay Therapeutics, Gracell Biotechnologies, INZY, Jasper Therapeutics, MIRM, XLO, ROIV.
- Octagon Capital Advisors was a net buyer of stock by $185M.
- Octagon Capital Advisors has $834M in assets under management (AUM), dropping by 33.50%.
- Central Index Key (CIK): 0001839435
Tip: Access up to 7 years of quarterly data
Positions held by Octagon Capital Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Octagon Capital Advisors
Octagon Capital Advisors holds 56 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Apellis Pharmaceuticals Call Option (APLS) | 21.2 | $177M | +7% | 3.0M | 58.78 |
|
| Alpine Immune Sciences (ALPN) | 5.9 | $49M | 1.2M | 39.64 |
|
|
| Dianthus Therapeutics (DNTH) | 5.0 | $41M | +149% | 1.4M | 30.00 |
|
| Verona Pharma Sponsored Ads (VRNA) | 4.6 | $38M | 2.4M | 16.09 |
|
|
| Dyne Therapeutics (DYN) | 4.2 | $35M | +56% | 1.2M | 28.39 |
|
| Arrivent Biopharma | 4.2 | $35M | NEW | 1.9M | 17.86 |
|
| Insmed Com Par $.01 (INSM) | 3.7 | $31M | -11% | 1.1M | 27.13 |
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 2.8 | $23M | 2.1M | 11.30 |
|
|
| Eyepoint Pharmaceuticals Com New (EYPT) | 2.7 | $23M | NEW | 1.1M | 20.67 |
|
| Ocular Therapeutix (OCUL) | 2.6 | $22M | NEW | 2.4M | 9.10 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 2.6 | $22M | +22% | 507k | 42.86 |
|
| Bridgebio Pharma (BBIO) | 2.6 | $21M | -2% | 690k | 30.92 |
|
| Mind Medicine Mindmed Com New (MNMD) | 2.4 | $20M | NEW | 2.2M | 9.40 |
|
| IsoRay (CATX) | 2.1 | $18M | NEW | 15M | 1.19 |
|
| Corbus Pharmaceuticals Hldgs Com New (CRBP) | 1.9 | $16M | NEW | 405k | 39.24 |
|
| Praxis Precision Medicines I Com New (PRAX) | 1.9 | $16M | NEW | 260k | 61.02 |
|
| Tenaya Therapeutics (TNYA) | 1.8 | $15M | NEW | 2.9M | 5.23 |
|
| Jasper Therapeutics Com New (JSPR) | 1.8 | $15M | NEW | 501k | 29.36 |
|
| Annexon (ANNX) | 1.8 | $15M | 2.1M | 7.17 |
|
|
| Cytokinetics Com New (CYTK) | 1.6 | $14M | +67% | 194k | 70.11 |
|
| Aerovate Therapeutics (AVTE) | 1.4 | $12M | 404k | 29.57 |
|
|
| Miragen Therapeutics (VRDN) | 1.3 | $11M | 620k | 17.51 |
|
|
| Gossamer Bio (GOSS) | 1.3 | $11M | 9.2M | 1.18 |
|
|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 1.2 | $9.6M | NEW | 408k | 23.65 |
|
| Glycomimetics (GLYC) | 1.1 | $9.0M | 3.0M | 3.00 |
|
|
| Immunovant (IMVT) | 1.1 | $8.8M | 273k | 32.31 |
|
|
| Taysha Gene Therapies Com Shs (TSHA) | 1.0 | $8.7M | NEW | 3.0M | 2.87 |
|
| Akero Therapeutics (AKRO) | 1.0 | $8.6M | NEW | 340k | 25.26 |
|
| Ventyx Biosciences (VTYX) | 1.0 | $8.3M | NEW | 1.5M | 5.50 |
|
| Cybin Ord (CYBN) | 0.9 | $7.7M | NEW | 19M | 0.41 |
|
| Arrowhead Pharmaceuticals (ARWR) | 0.9 | $7.2M | NEW | 250k | 28.60 |
|
| Mineralys Therapeutics (MLYS) | 0.9 | $7.1M | NEW | 550k | 12.91 |
|
| Silence Therapeutics Ads (SLN) | 0.8 | $6.8M | NEW | 315k | 21.60 |
|
| Pepgen (PEPG) | 0.7 | $5.5M | NEW | 376k | 14.70 |
|
| Vincerx Pharma Com New (VINC) | 0.6 | $5.1M | NEW | 1.0M | 5.06 |
|
| Nuvation Bio Com Cl A (NUVB) | 0.6 | $5.0M | +37% | 1.4M | 3.64 |
|
| Phathom Pharmaceuticals (PHAT) | 0.6 | $4.8M | +810% | 455k | 10.62 |
|
| Mersana Therapeutics (MRSN) | 0.5 | $4.5M | NEW | 1.0M | 4.48 |
|
| Terns Pharmaceuticals (TERN) | 0.5 | $4.1M | NEW | 625k | 6.56 |
|
| Fate Therapeutics (FATE) | 0.5 | $3.8M | NEW | 521k | 7.34 |
|
| Reneo Pharmaceuticals (RPHM) | 0.4 | $3.7M | 2.3M | 1.66 |
|
|
| Anaptysbio Inc Common (ANAB) | 0.4 | $3.7M | +37% | 165k | 22.52 |
|
| Sana Biotechnology (SANA) | 0.4 | $3.6M | NEW | 361k | 10.00 |
|
| An2 Therapeutics (ANTX) | 0.4 | $3.6M | +65% | 1.1M | 3.25 |
|
| Allogene Therapeutics (ALLO) | 0.4 | $3.2M | NEW | 720k | 4.47 |
|
| Allovir (ALVR) | 0.4 | $3.2M | NEW | 4.2M | 0.75 |
|
| Female Health (VERU) | 0.3 | $2.7M | 3.8M | 0.70 |
|
|
| Rapt Therapeutics (RAPT) | 0.3 | $2.6M | 292k | 8.98 |
|
|
| Nkarta (NKTX) | 0.3 | $2.6M | NEW | 240k | 10.81 |
|
| Helix Acquisition Corp Ii Cl A Ord Shs | 0.3 | $2.6M | NEW | 250k | 10.35 |
|
| Poseida Therapeutics I (PSTX) | 0.3 | $2.3M | NEW | 736k | 3.19 |
|
| Century Therapeutics (IPSC) | 0.3 | $2.3M | NEW | 540k | 4.18 |
|
| Adicet Bio (ACET) | 0.2 | $1.8M | NEW | 768k | 2.35 |
|
| Atyr Pharma Com New (LIFE) | 0.2 | $1.4M | NEW | 700k | 1.95 |
|
| Autolus Therapeutics Spon Ads (AUTL) | 0.1 | $1.1M | NEW | 176k | 6.38 |
|
| Cabaletta Bio (CABA) | 0.1 | $887k | NEW | 52k | 17.06 |
|
Past Filings by Octagon Capital Advisors
SEC 13F filings are viewable for Octagon Capital Advisors going back to 2020
- Octagon Capital Advisors 2024 Q1 filed May 15, 2024
- Octagon Capital Advisors 2023 Q4 filed Feb. 14, 2024
- Octagon Capital Advisors 2023 Q3 filed Nov. 14, 2023
- Octagon Capital Advisors 2023 Q2 filed Aug. 14, 2023
- Octagon Capital Advisors 2023 Q1 filed May 15, 2023
- Octagon Capital Advisors 2022 Q4 filed Feb. 14, 2023
- Octagon Capital Advisors 2022 Q3 filed Nov. 14, 2022
- Octagon Capital Advisors 2022 Q2 filed Aug. 15, 2022
- Octagon Capital Advisors 2022 Q1 filed May 16, 2022
- Octagon Capital Advisors 2021 Q4 filed Feb. 14, 2022
- Octagon Capital Advisors 2021 Q3 filed Nov. 15, 2021
- Octagon Capital Advisors 2021 Q2 filed Aug. 16, 2021
- Octagon Capital Advisors 2021 Q1 filed May 17, 2021
- Octagon Capital Advisors 2020 Q4 filed Feb. 16, 2021